GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Sanjiu Medical & Pharmaceutical Co Ltd (SZSE:000999) » Definitions » Research & Development

China Resourcesnjiu Medical & Pharmaceutical Co (SZSE:000999) Research & Development : ¥719 Mil (TTM As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is China Resourcesnjiu Medical & Pharmaceutical Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. China Resourcesnjiu Medical & Pharmaceutical Co's Research & Development for the three months ended in Mar. 2024 was ¥137 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was ¥719 Mil.


China Resourcesnjiu Medical & Pharmaceutical Co Research & Development Historical Data

The historical data trend for China Resourcesnjiu Medical & Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resourcesnjiu Medical & Pharmaceutical Co Research & Development Chart

China Resourcesnjiu Medical & Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 441.88 459.84 560.20 593.94 714.50

China Resourcesnjiu Medical & Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 132.60 162.61 163.23 256.06 137.42

China Resourcesnjiu Medical & Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥719 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Resourcesnjiu Medical & Pharmaceutical Co  (SZSE:000999) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


China Resourcesnjiu Medical & Pharmaceutical Co Research & Development Related Terms

Thank you for viewing the detailed overview of China Resourcesnjiu Medical & Pharmaceutical Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


China Resourcesnjiu Medical & Pharmaceutical Co (SZSE:000999) Business Description

Traded in Other Exchanges
N/A
Address
High-Tech Park, Lake Street Mission Hills, Longhua District, Shenzhen, CHN, 518110
China Resources Sanjiu Medical & Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in the research and development, production and sale of pharmaceutical products, healthcare products, and medical appliances under the brand name 999, which includes OTC, antibiotic and raw material drug. The other brands under which the company offers its products are Lee King, Shunfeng, and Tianhe. The company's core business is located in OTC and Chinese medicine prescription drugs, OTC core products in the cold, gastrointestinal, skin, pediatric, cough and orthopedic drugs occupy a higher market share; prescription drug products in traditional Chinese medicine formula granules, cardiovascular and cerebrovascular, anti-tumor in the field of anti-infection and other areas.
Executives
Yang Zhan Ao Executives
Independent director
Li De Ming Supervisors
Lin Xi Ping Supervisors
Fang Ming Director
Mai Yi Executives

China Resourcesnjiu Medical & Pharmaceutical Co (SZSE:000999) Headlines

No Headlines